Which funds bought or sold TEVAN in Q3 2026?
Teva Pharmaceutical Inds Ltd. 0 funds bought, 7 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$552M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- BlackRockOUT−$2.2B
- GeodeOUT−$391M
- WellingtonOUT−$260M
- GlenviewOUT−$172M
- DME / GreenlightOUT−$98M
- DuquesneOUT−$21M
- FarallonOUT−$1M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (0)
None of the tracked funds.
Sold (7)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| BlackRock Index giant | Sold out | −$2.2B | — |
| Geode Index giant | Sold out | −$391M | — |
| Wellington Asset manager | Sold out | −$260M | — |
| Glenview Hedge fund | Sold out | −$172M | — |
| DME / Greenlight Value investor | Sold out | −$98M | — |
| Duquesne Family office & foundation | Sold out | −$21M | — |
| Farallon Hedge fund | Sold out | −$1M | — |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.